CD163 and Parkinson disease: In Parkinson disease rat models, delivery of CD163-targeted liposomes containing DEXA provided protection against 6-OHDA-induced dopaminergic neurodegeneration, which correlated with a distinctive microglia response (Tentillier et al. 2016).